A Phase 3 interventional study of Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml in Delirium and Critical Illness, sponsored by Deventer Ziekenhuis. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-30.
Sponsored by Deventer Ziekenhuis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Delirium with a site in Netherlands — 3 open to participants now, 3 under way, 1 of them phase 3. Delirium · Netherlands.
Among the 31 studies in Delirium with a site in Netherlands, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 16th registered.
935 studies on the registry are indexed under Delirium; 188 are open to participants now.
Browse Delirium studies →3 of the 31 studies in Delirium with a site in Netherlands are open now. Recruiting first, the newest first:
A.J.C. Slooter · Sites in Netherlands
Ages 50+
UMC Utrecht · Sites in Netherlands
Ages 18+
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 111 across 551 interventional studies indexed under Delirium.
Median enrollment 174 across the 18 interventional studies, 650 across the 13 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 31 have an industry lead sponsor. The 10 most frequent:
Deventer Ziekenhuis is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Deventer Ziekenhuis has 2 studies filed under Delirium — fewer than ten, so there is no comparison to draw.
1 of the studies in Delirium with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06285721A.J.C. SlooterDelirium Treatment With Transcranial Electrical Stimulation | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Delirium with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is developed for assessing the pharmacodynamic and pharmacokinetic properties of intravenous (IV) clonidine in critically ill patients on the ICU, and to estimate the optimal dosing strategy for IV clonidine.
Many patients in intensive care units (ICU's) require sedation and analgesia to tolerate mechanical ventilation and other ICU procedures. Commonly used GABA-ergic anaesthetics like propofol, midazolam and morphine have potential adverse effects that may increase morbidity, prolong ICU stay and provoke delirium. Recent studies have shown that sedation with alpha-2-adrenergic agonists may lead to a reduction of the total amount of gamma-aminobutyric acid (GABA) -ergic anaesthetics and reduction of delirium1In clinical practice the alpha-2-adrenergic agent clonidine is widely used off label as an add-on sedative in mechanically ventilated patients who suffer from delirium, but there are no large studies proving that this therapy is effective and safe. Limited information exists on the pharmacokinetics of iv clonidine, especially in ICU patients. Besides, dosing regimens of clonidine differ widely among ICU's in the Netherlands, and in the literature.
The sample size required for pharmacokinetic modelling with an acceptable level of precision is inversely related to the number of blood samplings taken from each individual. Population pharmacokinetic experiments that have been published have generally used 50 or more subjects. However, in the investigators study a relatively large number of blood samples are taken (>10 per subject when the protocol is completed, see section 6.3). THe investigators estimate that sufficient precision can be obtained with a sample size of 24 subjects, generating an estimated 240 to 360 blood samples.
In a recent publication of a computer simulated population pharmacokinetics of an absorption model using a design that involved 6 samplings per subject, it was estimated that a two-compartment first-order model would need 50 subjects (i.e. 300 blood samplings) to obtain a model with 50% precision and a power of 0.8.
The investigators 24 subjects will be treated with 3 different doses of clonidine (600, 1200 and 1800 µg/day), that is 8 per treatment arm.
On top of this, 8 patients receiving no clonidine will serve as a reference group, in order to interpret hemodynamic and safety data, and to illustrate dose-response relationships.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, a subject must be:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms
4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.
Drug: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
* 4 patients receive 1200 µg/day of clonidine without loading schedule. * 4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h.
Drug: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
* 4 patients receive 1800 µg/day of clonidine without loading schedule. * 4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h.
Drug: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
Drug page: ClonidineStudies of ClonidineClonidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
clonidine intravenous
Also known as: Boehringer Ingelheim, RVG 06055
clonidine plasma concentrations
pharmacokinetic and pharmacodynamic properties of intravenous clonidine in ICU patients Clonidine plasma concentration at start of infusion at t=2, t=4, t=8 and t=12 h Clonidine plasma concentration during study, once daily Clonidine plasma concentration after stopping infusion at t=ω+8, t=ω+16, t=ω+24 h, and t=ω+48 h (ω= end of infusion).
Time frame: up to 7 days
heart rate
Heart rate 2-hrly for the first 12 h, 8-hrly thereafter
Time frame: up to 7 days
blood pressure
Blood pressure 2-hrly for the first 12 h, 8-hrly thereafter
Time frame: up to 7 days
delirium
delirium rating scale, CAM-ICU 3 times daily
Time frame: up to 7 days
use of antipsychotics
additional use of haloperidol or sedatives, measured in total amount during the investigational period
Time frame: up to 7 days
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2016, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clonidine
Deventer Ziekenhuis